Synapse - Works

Results (115370)

The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results

Meeting Abstract

Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma

Meeting Abstract

Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Patients with out of specification tisagenlecleucel can be salvaged with a point‐of‐care car T‐cells: An observational intention‐to‐treat single‐center analysis

Meeting Abstract

Fried, S.; Shouval, R.; Varda‐Bloom, N.; Besser, M.; Yerushalmi, R.; Shem‐Tov, N.; Danylesko, I.; Jacoby, E.; Teihman, S.; Shimoni, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Pirtobrutinib (LOXO‐305), a next generation highly selective non‐covalent BTK inhibitor in previously treated richter transformation: Results from the phase 1/2 bruin study

Meeting Abstract

Jurczak, W.; Shah, N. N.; Lamanna, N.; Eyre, T. A.; Woyach, J.; Lech‐Maranda, E.; Wierda, W. G.; Lewis, D.; Thompson, M. C.; Wang, D.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Preliminary activity of devimistat (CPI 613) in patients with relapsed or refractory Burkitt lymphoma/leukemia

Meeting Abstract

Nikolaenko, L.; Pardee, T. S.; Steiner, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez-Rivera, I.; Straus, D.; Luther, S.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

ESCALADE: A phase 3 study of acalabrutinib in combination with R‐CHOP for patients ≤65y with untreated non‐germinal center B‐cell–like diffuse large B‐cell lymphoma

Meeting Abstract

Sehn, L. H.; Kahl, B.; Matasar, M.; Lentz, G.; Izutsu, K.; Zhao, W.; Tao, L.; Calvo, R.; Zinzani, P. L.
Hematological Oncology (2021)

Fulltext@MSK | Save

Nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (CHL) after autologous transplantation: 5‐year overall survival from the phase 2 CheckMate 205 study

Meeting Abstract

Ansell, S. M.; Bröckelmann, P. J.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G. P.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T‐cell lymphoma with less than 10% CD30 expression (SGN35‐032, trial in progress)

Meeting Abstract

Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
Hematological Oncology (2021)

Fulltext@MSK | Save

New prognostic score incorporating MTV predicts treatment failure in advanced Hodgkin lymphoma

Meeting Abstract

Barrington, S. F.; Kirkwood, A. A.; Pike, L. C.; Guezennec, C.; Li, H.; le Blanc, M.; Poon, D.; Knopp, M. V.; Clifton‐Hadley, L.; Laubach, C.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Outcomes in later‐lines of therapy for relapsed/refractory follicular lymphoma: Results from the international SCHOLAR‐5 study

Meeting Abstract

Ghione, P.; Ghesquieres, H.; Bobillo, S.; Patel, A. R.; Kanters, S.; Deighton, K.; Dong, H.; Yang, Y.; Ma, L.; Limbrick‐Oldfield, E. H.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save